首页> 外文期刊>Social science and medicine >Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine
【24h】

Standardization as situation-specific achievement: Regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine

机译:标准化是针对具体情况的成就:干细胞医学的洲际合作中的监管多样性和价值创造

获取原文
获取原文并翻译 | 示例
           

摘要

The article examines the role and challenges of scientific self-governance and standardization in intercontinental clinical research partnerships in stem cell medicine. The paper shows that - due to a high level of regulatory diversity - the enactment of internationally recognized standards in multi-country stem cell trials is a complex and highly situation-specific achievement. Standardization is imposed on a background of regulatory, institutional and epistemic-cultural heterogeneity, and implemented exclusively in the context of select clinical projects. Based on ethnographic data from the first transcontinental clinical trial infrastructure in stem cell medicine between China and the USA, the article demonstrates that locally evolved and international forms of experimental clinical research practices often co-exist in the same medical institutions. Researchers switch back and forth between these schemas, depending on the purposes of their research, the partners they work with, the geographic scale of research projects, and the contrasting demands for regulatory review, that result from these differences. Drawing on Birch's analysis of the role of standardization in international forms of capital production in the biosciences, the article argues that the integration of local knowledge institutions into the global bioeconomy does not necessarily result in the shutting down of localized forms of value production. In emerging fields of medical research, that are regulated in highly divergent ways across geographical regions, the coexistence of distinct modes of clinical translation allows also for the production of multiple forms of economic value, at varying spatial scales. This is especially so in countries with lenient regulations. As this paper shows, the long-standing absence of a regulatory framework for clinical stem cell applications in China, permits the situation-specific adoption of internationally recognized standards in some contexts, while enabling the continuation of localized forms of value production in others.
机译:本文探讨了科学自我管理和标准化在干细胞医学的洲际临床研究合作伙伴关系中的作用和挑战。该文件表明-由于高度的监管多样性-在多国干细胞试验中制定国际认可的标准是一项复杂且高度针对具体情况的成就。标准化是在监管,机构和认知文化异质性的背景下强加的,并且仅在特定的临床项目中实施。基于中国和美国之间第一个干细胞医学跨大陆临床试验基础设施的人种学数据,本文证明,本地发展和国际形式的实验临床研究实践通常在同一医疗机构中共存。研究人员会在这些模式之间来回切换,具体取决于研究目的,合作伙伴,研究项目的地理规模以及因这些差异而产生的对监管审查的不同需求。根据伯奇对标准化在生物科学中国际资本生产形式中的作用的分析,文章认为,将地方知识机构整合到全球生物经济中并不一定会导致本地化价值生产形式的关闭。在新兴的医学研究领域中,跨越地理区域以高度不同的方式进行监管,不同临床翻译模式的共存还允许在不同的空间规模上产生多种形式的经济价值。在法规宽松的国家尤其如此。正如本文所表明的那样,中国长期以来缺乏针对临床干细胞应用的监管框架,允许在某些情况下根据情况采用国际认可的标准,而在其他情况下则可以继续本地化的价值生产形式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号